Hi, what are you looking for?
By Josh Beckerman
Shares of Journey Medical were up 21%, to $2.03, as it reported favorable topline Phase 1 study data for a papulopustular rosacea treatment it is developing in collaboration with Dr. Reddy’s Laboratories.
Journey Medical said it is “very pleased” with the results for DFD-29, which indicate that it can be safely used for up…
Read the full article here
This week’s Fed meeting is extraordinary, and it could shock investors in a way we haven’t seen since 2008. So, I’m doing the weekly...
This article was written by Follow Leo Nelissen is an analyst focusing on major economic developments related to supply chains, infrastructure, and commodities. He...
